| Document |
Document Title |
|
WO/2021/207530A1 |
The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e g., splicing of a pre-mRNA, as well as methods of use thereof.
|
|
WO/2021/202137A1 |
The present technology is directed to methods of treatment utilizing inhibitors of HuR interaction with RNA, where the inhibitors are of Formula I where R1 is; and X1 is OH, NH-OH, or 0-(C1-C8 unsubstituted alkyl).
|
|
WO/2021/195781A1 |
Disclosed are compounds and pharmaceutically acceptable salts thereof that may be used in the treatment of subjects in need thereof. The compounds disclosed herein may be inhibitors of tyrosine and threonine-specific cdc2-inhibitory kina...
|
|
WO/2021/198239A1 |
The invention relates to a compound of formula I: wherein - A is present or absent; - X1, X2, X3 and X4 are, independently from each other, an alkyl; - Y1, Y2, Y3 and Y4 are independently from each other a C1-C10 alkyl, - Z1, Z2, Z3 and ...
|
|
WO/2021/202452A1 |
Disclosed herein is an improved process for the synthesis of compound (A): (A), or a salt or solvate thereof via methylation of compound (B): (B), or a salt or solvate thereof, a crystalline hydrate of compound A, and pharmaceutical form...
|
|
WO/2021/190615A1 |
Provided are novel casein kinase inhibitors, or pharmaceutically acceptable salts thereof. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also provided.
|
|
WO/2021/193756A1 |
A benzimidazole derivative represented by formula (I) (wherein A1 to A3 and R1 to R6 are as described in the description) or a pharmaceutically acceptable salt thereof, which inhibits activation of STING pathway and, therefore, which is ...
|
|
WO/2021/190467A1 |
The present invention relates to a compound as represented by general formula (1), and a preparation method therefor and the use of the compound of formula (1) and isomers, crystal forms and pharmaceutically acceptable salts thereof as i...
|
|
WO/2021/190727A1 |
The invention provides novel compounds having the general formula (I) wherein R1, R2, R3a, R3b, R4, A1, A2, A3, A4, A5, A6, B1, B2, B3, B4, and L are as described herein, compositions including the compounds and methods of using the comp...
|
|
WO/2021/193818A1 |
The purpose of the present invention is to provide: a crystal of a phenanthroline derivative, said crystal having high chemical purity and low residual solvent content, thereby being suitable for use as a light emitting element material;...
|
|
WO/2021/194878A1 |
Bifunctional compounds, which find utility as modulators of non-receptor Leucine-rich repeat kinase 2 (LRRK2), are described herein. In particular, the bifunctional compounds of the present disclosure contain on one end a moiety that bin...
|
|
WO/2021/186855A1 |
Provided is a novel method for detecting an indicator of T-cell lymphoma. This method for detecting an indicator of T-cell lymphoma comprises a step for detecting acetylated tubulin in T cells collected from a subject.
|
|
WO/2021/179996A1 |
Provided is a solid form of a citrate of compound (I) used as a BTK inhibitor, particularly crystal form I and crystal form II, a preparation method therefor, and application thereof in the preparation of drugs for treating diseases.
|
|
WO/2021/177330A1 |
The present invention provides a compound which has a PDHK inhibitory activity and is useful for treating or preventing diabetes (type 1 diabetes, type 2 diabetes, etc.), insulin resistance syndrome, metabolic syndrome, hyperglycemia, hy...
|
|
WO/2021/174174A1 |
The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof. Formula (I-b).
|
|
WO/2021/172185A1 |
The purpose of the present invention is to provide: a fused polycyclic aromatic compound having excellent heat resistance in a practical process temperature range; an organic thin film containing said compound; and an organic semiconduct...
|
|
WO/2021/169963A1 |
Provided are a compound containing an aromatic group as well as a stereoisomer, a tautomer or a pharmaceutically acceptable salt of the compound. Further provided is a method related to preparation and use of the compound. A pharmaceutic...
|
|
WO/2021/169933A1 |
Provided in the present invention are a compound as represented by general formula (I) for treating biliary tract cancer or a pharmaceutically acceptable salt, a stereisomer or a crystal form thereof, a pharmaceutical composition contain...
|
|
WO/2021/168341A1 |
The present application relates to two crystalline polymorphic forms, crystalline methanol, ethanol and tetrahydrofuran solvates and a crystalline hydrate of the compound l-(5-(3-(7-(3-fluorophenyl)-3H- imidazo[4,5-c]pyridin-2-yl)-1H-pyr...
|
|
WO/2021/168197A1 |
The present disclosure provides bifunctional compounds as IRAK4 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by IRAK4.
|
|
WO/2021/162057A1 |
This organic electroluminescent element (1) includes at least two light emitting units (11, 12) arranged between an anode (3) and a cathode (4), and a first cathode-side organic layer (21), wherein: the first cathode-side organic layer (...
|
|
WO/2021/157600A1 |
Compounds represented by the general formula are useful as luminescent materials. R1 or R2 is Het-LA-* or CN-LA-*; one to three among R1-R5 are diarylamino groups, etc.; the remainder are hydrogen atoms or aryl groups; Het is a heteroary...
|
|
WO/2021/157642A1 |
The present invention improves the light emission efficiency, driving voltage, and lifespan of an organic electroluminescent element using a delayed fluorescent material. A host material for a delayed fluorescent material and comprising ...
|
|
WO/2021/157593A1 |
Superior durability is demonstrated by an organic light emitting element that uses a light emitting composition including both a first compound with a PBHT value greater than 0.730 and a second compound for which ES1 is smaller than for ...
|
|
WO/2021/158698A1 |
The present invention relates to compounds of Formula (Ia), pharmaceutically acceptable salts of compounds of Formula (Ia), and pharmaceutical compositions thereof that modulate the activity of the muscarinic acetylcholine receptor M4. C...
|
|
WO/2021/156180A1 |
The present invention relates to new [1,3]diazino[5,4-d]pyrimidines and derivatives of Formula (I) wherein the groups R1, R2, R3 and R4 have the meanings given in the claims and specification, their use as inhibitors of HER2 and its muta...
|
|
WO/2021/151919A1 |
The present invention relates to picolinic acid derivatives that are useful in treating fungal diseases, particularly fungal diseases of agricultural crop plants.
|
|
WO/2021/147790A1 |
The present invention relates to a pyrazolo[1,5-a]pyrazine derivative and a preparation method therefor and a use thereof in medicines. In particular, the present invention relates to a pyrazolo[1,5-a]pyrazine derivative shown in general...
|
|
WO/2021/146370A1 |
One embodiment of the disclosure is a compound represented by Formula I or a pharmaceutically acceptable salt thereof. The variables in Formula I are defined herein. Compounds of Formula I are selective MAP4K1 inhibitors, which can be us...
|
|
WO/2021/144582A1 |
Latent photoinitiator compounds are described, as well as compositions containing such compounds and their uses in photoinitated methods for producing photoresist structured.
|
|
WO/2021/146211A1 |
Provided herein are nanoparticle compositions comprising a pharmaceutically acceptable carrier and a compound of Formula (II).
|
|
WO/2021/143680A1 |
The present invention relates to a heteroaryl derivative, a preparation method therefor, and an application thereof in medicine. Specifically, the present invention relates to a heteroaryl derivative as represented by general formula (AI...
|
|
WO/2021/145401A1 |
The present invention relates to spiroheterocyclic derivatives which have antagonistic activities against CRHR2, and which are useful in the treatment or prevention of disorders and diseases in which CRHR2 is involved. The invention also...
|
|
WO/2021/146424A1 |
The present disclosure relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.
|
|
WO/2021/143833A1 |
Provided are a high-yield eurotium cristatum strain containing a diketopiperazine dimer, a method for separating and purifying the diketopiperazine dimer therefrom, and a use of a diketopiperazine dimer in the preparation of a hypoglycem...
|
|
WO/2021/139814A1 |
Provided is a quinoline imidazole compound, and specifically disclosed are the compound of formula (I) and a pharmaceutically acceptable salt thereof.
|
|
WO/2021/139817A1 |
Provided in the present invention is a polycyclic compound, which acts as a kinase inhibitor. Specifically, provided in the present invention is a compound of the structure shown in formula (I) below (each group is defined as specified i...
|
|
WO/2021/141106A1 |
The present invention provides a compound having an excellent control effect against harmful arthropods. A compound represented by formula (I), or an N oxide thereof, has an excellent control effect against harmful arthropods. [In the fo...
|
|
WO/2021/142252A1 |
Disclosed are compounds of Formula I, methods of using the compounds for inhibiting KRAS activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or dis...
|
|
WO/2021/141041A1 |
Provided is a therapeutic agent and/or prophylactic agent for tauopathies that is based on the activation of voltage-gated sodium channels (Nav). The therapeutic agent and/or prophylactic agent for tauopathies has an Nav activator as an ...
|
|
WO/2021/134854A1 |
The present invention relates to a new vulcanizing agent and the use thereof in a polymer. The vulcanizing agent is added during the processing of a polymer, and can form a cross-linked network in the polymer, thereby improving the mecha...
|
|
WO/2021/135261A1 |
The present invention relates to the technical field of organic semiconductors, and aims to provide an aromatic amine compound and an application thereof in an optoelectronic device. The compound is composed of an N,N-dialkyldicarbazol a...
|
|
WO/2021/135482A1 |
A water-soluble conjugated polymer for photothermal therapy, a polymerized monomer thereof, a preparation method therefor, and application thereof. The water-soluble conjugated polymer has good solubility in an aqueous solution, has exce...
|
|
WO/2021/138419A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...
|
|
WO/2021/136034A1 |
An organic compound having a structure represented by formula (1), wherein Ar1, Ar2 and Ar3 are the same or different, and are each independently selected from a substituted or unsubstituted aryl group having 6-30 carbon atoms, a substit...
|
|
WO/2021/130638A1 |
The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compo...
|
|
WO/2021/129824A1 |
The present invention relates to a compound as shown in formula (1) and a preparation method therefor, and use of the compound of formula (1), optical isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates thereo...
|
|
WO/2021/133809A1 |
The present disclosure provides a compound represented by structural formula (I) : or a pharmaceutically acceptable salt thereof useful for treating a cancer.
|
|
WO/2021/132524A1 |
[Problem] To provide an epoxy azepan derivative having an agonist activity against κ-opioid receptor. [Solution] An azepan derivative represented by general formula (I) or a pharmaceutically acceptable salt thereof is used as an analget...
|
|
WO/2021/129841A1 |
The present invention relates to a compound used as an RET kinase inhibitor and an application thereof. The compound has a structure represented by formula F, has a good inhibitory ability for RET kinase, and has relatively good pharmaco...
|
